If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Lung cancer is the leading cause of cancer death in the United States and around the world. Almost as many Americans die of lung cancer every year than die of prostate, breast, and colon cancer combined (Fig. 1).
The statistics reflect data from 2007 and, therefore, likely underestimate the current lung cancer burden. Lung cancer has been the most common cancer worldwide since 1985, both in terms of incidence and mortality. Globally, lung cancer is the largest contributor to new cancer diagnoses (1,350,000 new cases and 12.4% of total new cancer cases) and to death from cancer (1,180,000 deaths and 17.6% of total cancer deaths). The 5-year survival rate in the United States for lung cancer is 15.6%, and although there has been some improvement in survival during the past few decades, the survival advances that have been realized in other common malignancies have yet to be achieved in lung cancer. There has been a large relative increase in the numbers of cases of lung cancer in developing countries. Approximately half (49.9%) of the cases now occur in developing countries whereas in 1980, 69% of cases were in developed countries. The estimated numbers of lung cancer cases worldwide has increased by 51% since 1985 (a 44% increase in men and a 76% increase in women). In the United States, cancer of the lung and bronchus ranks second in both genders, with an estimated 115,060 new cases in men (14% of all new cancers) and 106,070 in women (14% of all new cancers).
Lung cancer in both genders tops the list on the number of estimated deaths yearly (85,600, or 28% of all cancer deaths for men, and 71,340, or 26% of all cancer deaths for women) (Fig. 2).
Lung cancer incidence in men in the United States has been decreasing since the early 1980s. The incidence and mortality rates for lung cancer tend to mirror one another because most patients diagnosed with lung cancer eventually die of it. Siegel and colleagues,
in their review of cancer statistics in 2011, noted decreases in death rates from lung cancer in men by 2.0% per year from 1994 to 2006 (Fig. 3). In women, however, lung cancer death rates continued to increase by 0.3% per year from 1995 to 2005, but more recent data from 2003 to 2006 show a more encouraging trend with a start in decline of 0.9% per year (see Figs. 3 and 4). The lung cancer incidence among women has declined over the past decades, from 5.6% between 1975 and 1982, to 3.4% between 1982 and 1990, to 0.4% between 1991 and 2006, and more recently to –2.3% between 2006 and 2008 (see Fig. 4). Because of the change in lung cancer incidence in women, recent figures show that lung cancer death rates decreased in women for the first time, more than a decade after decreases in men.
The lag in the decline of lung cancer rates in women compared with men has been attributed to the fact that cigarette smoking in women peaked two decades later than in men. Lung cancer mortality rates thus seem to be reaching a plateau, which is an encouraging change from the steep rise in the 1970s (see Fig. 3).
The Surveillance, Epidemiology and End Results (SEER) data from 2004 to 2008 reported the median age at diagnosis for cancer of the lung and bronchus as 71 years (Fig. 5). No cases were diagnosed in patients younger than 20 years (see Fig. 5).
Approximately 0.2% of lung cancers was diagnosed in patients between age 20 and 34 years; 1.5% between 35 and 44 years; 8.8% between 45 and 54 years; 20.9% between 55 and 64 years; 31.1% between 65 and 74 years; 29% between 75 and 84 years; and 8.3% at 85 years and older.
Lung cancer arises from the cells of the respiratory epithelium and can be divided into two broad categories. Small cell lung cancer (SCLC) is a highly malignant tumor derived from cells exhibiting neuroendocrine characteristics and accounts for 15% of lung cancer cases. Non–small cell lung cancer (NSCLC), which accounts for the remaining 85% of cases, is further divided into 3 major pathologic subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Adenocarcinoma by itself accounts for 38.5% of all lung cancer cases, with squamous cell carcinoma accounting for 20% and large cell carcinoma accounting for 2.9%.
In the past several decades, the incidence of adenocarcinoma has increased greatly, and adenocarcinoma has replaced squamous cell carcinoma as the most prevalent type of NSCLC. The 5-year total survival rate for lung cancer in the United States from 2001 to 2007 was 15.6%. Patients with localized disease at diagnosis have a 5-year survival rate of 52%; however, the more than 52% of patients with distant metastasis at diagnosis have a dismal 5-year survival rate of 3.6%, which begs for the need for better screening methods to detect early-stage cancers (Fig. 6). (See article elsewhere in this issue by Mithun.)
Lung cancer was the most commonly diagnosed cancer and the leading cause of cancer death in men in 2008 globally.
For women, lung cancer was the fourth most commonly diagnosed cancer and the second leading cause of cancer death. Overall, lung cancer accounted for 13% or 1.6 million of total cancer cases and 18% or 1.4 million cancer-related deaths worldwide in 2008. Lung cancer incidence and mortality rates are highest in the United States and the developed countries. In contrast, lung cancer rates in underdeveloped geographic areas, including Central America and most of Africa, are lower, except the rates are slowly increasing (Fig. 7A). More developed countries have higher incidence and mortality rates from lung cancers in both genders than less developed countries (see Fig. 7B, C). The World Health Organization estimates that lung cancer deaths worldwide will continue to rise, largely as a result of an increase in global tobacco use, especially in Asia. Tobacco use is the principal risk factor for lung cancer, and a large proportion of all pulmonary carcinomas are attributable to the effects of cigarette smoking.
Of these, 79.8% (36.7 million) smoke every day and 20.2% (9.3 million) smoke some days. During the past decade, there has been a 3.5% point decrease in the number of US adults who smoke (20.6% in 2008 and 24.1% in 1998).
Despite the availability of new diagnostic and genetic technologies, advancements in surgical techniques, and the development of new biologic treatments, the overall 5-year survival rate for lung cancer in the United States remains at a dismal 15.6%.
The situation globally is even worse, with 5-year survival in Europe, China, and developing countries estimated at only 8.9%.
This introductory article to the current edition of Clinics in Chest Medicine dedicated to lung cancer focuses on modifiable risk factors, including tobacco smoking, occupational carcinogens, diet, and ionizing radiation. It also discusses briefly the molecular and genetic aspects of lung carcinogenesis.
Etiology of lung cancer
Tobacco has been part of the cultural and economic structure of this country since the time of Columbus. Originally chewed or smoked in pipes, tobacco became widely available in cigarette form after the development of cigarette wrapping machinery in the mid-1800s. Before World War I, cigarette use in the United States was modest. Wynder and Graham estimated that the average adult smoked fewer than 100 cigarettes per year in 1900.
That seminal report stated the following important principal findings. (1) Cigarette smoking was associated with a 70% increase in the age-specific death rates of men and a lesser increase in the death rates of women. (2) Cigarette smoking was causally related to lung cancer in men. The magnitude of the effect of cigarette smoking far outweighed all other factors leading to lung cancer. The risk for lung cancer increased with the duration of smoking and the number of cigarettes smoked per day. The report estimated that the average male smoker had an approximately 9-fold to 10-fold risk for lung cancer, whereas heavy smokers had at least a 20-fold risk. (3) Cigarette smoking was believed more important than occupational exposures in the causation of lung cancer in the general population. (4) Cigarette smoking was the most important cause of chronic bronchitis in the United States. (5) Male cigarette smokers had a higher death rate from coronary artery disease than male nonsmokers.
The report concluded, “Cigarette smoking is a health hazard of sufficient importance in the United States to warrant appropriate remedial action.” Since the publication of the report, yearly per capita consumption of cigarettes has declined in the United States (see Fig. 8).
It is estimated that 20.6% of all American adults over age 18 years continue to smoke, a figure that has only minimally decreased since approximately 1997, based on a recent Morbidity and Mortality Weekly Report report by Dube and colleagues.
Of these smokers, 80.1% (36.3 million people) smoke every day and 19.9% (9 million) smoke some days. More men (23.5%) than women (17.9%) smoke. The decline in smoking rates is steeper for black men and white men than for white women and black women. The prevalence of smoking is 31.1% among persons below the federal poverty level. For adults older than 25 years, the prevalence of smoking was 28.5% among persons with less than a high school diploma compared with 5.6% among persons with a graduate degree.
in an extensive review of autopsy reports from hospitals in the United States and western Europe, which found 374 cases of primary lung cancer. This represented less than 0.5% of all cancer cases. He concluded, “primary malignant neoplasms of the lung are among the rarest forms of disease.” In 1920, lung cancer constituted only 1% of all malignancies in the United States. During the next several decades, researchers in the United States and abroad noted a significant increase in the incidence of carcinoma of the lung. In a series of 185,434 autopsy cases collected between 1897 and 1930, Hruby and Sweany
showed the degree of adverse effect on longevity increased with the amount of smoking (Fig. 9). The finding that tar applied to the skin of animals produced lung carcinoma raised concern that inhalation of tar products could be an important factor in the increase in lung cancer incidence. Observations in patients and experimental studies in animals have shown that tobacco tar liberated from the burning of tobacco was a carcinogenic agent.
In 1941, Ochsner and DeBakey stated in their review of lung carcinoma, “it is our definite conviction that the increase in the incidence of pulmonary carcinoma is due largely to the increase in smoking.”
examined 605 cases of lung cancer in men compared with a general male hospital population without cancer. The American investigators found that 96.5% of lung cancers were in men who were moderate to heavy smokers for many years. The authors concluded, (1) the excessive and prolonged use of tobacco was an important factor in the induction of lung cancer; (2) lung cancer in a nonsmoker was rare (however, this is currently not the case [discussed later in section on never smokers]); and (3) there could be a lag period of 10 years or more between cessation of smoking and the clinical onset of carcinoma. Subsequently, the Surgeon General of the United States re-emphasized in 2004 the conclusions of the 1964 report that “cigarette smoking is the major cause of lung cancer.”
Cigarette smoke is a complex aerosol composed of gaseous and particulate compounds. The smoke consists of mainstream smoke and sidestream smoke components. Mainstream smoke is produced by inhalation of air through the cigarette and is the primary source of smoke exposure for the smoker. Sidestream smoke is produced from smoldering of the cigarette between puffs and is the major source of environmental tobacco smoke (ETS). The primary determinant of tobacco addiction is nicotine, and tar is the total particulate matter of cigarette smoke after nicotine and water have been removed. Exposure to tar seems to be a major component of lung cancer risk. The Federal Trade Commission determines the nicotine and tar content of cigarettes by measurements made on standardized smoking machines. The composition of mainstream smoke, however, can vary greatly depending on the intensity of inhalation by a smoker. Although the use of filter tips decreases the amount of nicotine and tar in mainstream smoke, the effect of filter tips also varies because the compression of the tips by lips or fingers and the depth of inhalation of the smoker. There are more than 4000 chemical constituents of cigarette smoke: 95% of the weight of mainstream smoke comes from 400 to 500 gaseous compounds
; the rest of the weight is made up of more than 3500 particulate components.
Mainstream smoke contains many potential carcinogens, including polycyclic aromatic hydrocarbons (PAHs), aromatic amines, N-nitrosamines, and other organic and inorganic compounds, such as benzene, vinyl chloride, arsenic, and chromium. The PAHs and N-nitrosamines require metabolic activation to become carcinogenic. Metabolic detoxification of these compounds can also occur, and the balance between activation and detoxification likely affects individual cancer risk. Radioactive materials, such as radon and its decay products, bismuth, and polonium, are also present in tobacco smoke.
The International Agency for Research on Cancer (IARC) has identified at least 50 carcinogens in tobacco smoke.
The agents that seem of particular concern in lung carcinoma are the tobacco-specific N-nitrosamines (TSNAs) formed by nitrosation of nicotine during tobacco processing and during smoking. Eight TSNAs have been described, including 4-(methylnitrosamino)-1(3-pyridyl)-1-butanone (NNK), which is known to induce adenocarcinoma of the lung in experimental animals. Other TSNAs have been linked to cancer of the esophagus, bladder, pancreas, oral cavity, and larynx. Of the TSNAs, NNK, which seems the most important inducer of lung cancer, has carcinogenic effects with both topical and systemic administration. TSNAs are directly delivered to the lung by inhalation of tobacco smoke. TSNAs are also absorbed systemically, and hematogenous delivery to the lung can occur by way of the pulmonary circulation.
The dosage of smoke constituents received depends not only on the cigarette itself but also on the duration and intensity of inhalation, the presence and competence of a filter, and the duration of cooling of the smoke before inhalation. The primary factor determining intensity of cigarette use is the nicotine dependence of the smoker, and although cigarettes now contain less nicotine and tar than in the past, smokers tend to smoke more intensively with higher puffs per minute and deeper inhalations to satisfy their nicotine need. Therefore, the measurements of tar and nicotine content made by smoking machines may significantly underestimate individual exposure. Low-yield filtered cigarettes might be a contributing factor to the increase in the incidence of adenocarcinoma of the lung.
The nicotine-addicted smoker smokes low-yield cigarettes far more intensively than nonfiltered higher-yield cigarettes, and with deeper inhalation, higher-order bronchi in the peripheral lung are exposed to carcinogen-containing smoke as opposed to the major bronchi alone. These peripheral bronchi lack protective epithelium and are exposed to carcinogens, including TSNAs, which have been linked to the induction of adenocarcinoma.
Tobacco carcinogens, such as NNK, can bind to DNA and create DNA adducts, which are pieces of DNA covalently bonded to a cancer-causing chemical, such as PAH in cigarette smoke. Repair processes may remove these DNA adducts and restore normal DNA, or cells with damaged DNA may undergo apoptosis. Failure of the normal DNA repair mechanisms to remove DNA adducts, however, can lead to permanent mutations. NNKs can mediate an array of signaling pathway activation that includes modulation of critical oncogenes and tumor suppressor genes that ultimately can result in uncontrolled cellular proliferation and tumorigenesis.
This may in part explain the persistent elevation in lung cancer risk in exsmokers even years after discontinuing cigarette use. In addition, a specific chemical constituent of tobacco smoke, benzo[a]pyrene metabolite, can damage various p53 tumor-suppressor gene loci that are known to be abnormal in approximately 60% of primary lung cancer cases.
The cumulative lung cancer risk among heavy smokers can be as high as 30% compared with a lifetime risk of less than 1% in nonsmokers. The lung cancer risk is proportional to the quantity of cigarette consumption, because factors, such as the number of packs per day smoked, the age of onset of smoking, the degree of inhalation, the tar and nicotine content of cigarettes, and use of unfiltered cigarettes, become important.
There is no question that tobacco smoking remains the most important modifiable risk factor for lung cancer. It has been estimated that up to 20% of all cancer deaths worldwide could be prevented by the elimination of tobacco smoking.
It is also clear that individual susceptibility is a factor in carcinogenesis. Although more than 80% of lung cancers occur in persons with tobacco exposure, fewer than 20% of smokers develop lung cancer. This variability in cancer susceptibility is likely affected by other environmental factors or by genetic predisposition.
Other Types of Smoking
Other forms of tobacco use, such as cigar smoking and pipe smoking, have been associated with increased risk for lung cancer. The risk seems weaker, however, than with cigarette smoking. Most cigars are composed of primarily of a single type of tobacco that is air cured and fermented but can vary in their size and shape to contain from 1 g to 20 g of tobacco. Smoking 5 cigars a day on average is equivalent to smoking 1 pack a day of cigarettes. A large prospective study of more than 130,000 men over 12 years showed that cigar smokers have a relative risk of lung cancer of 5.1 compared with non–cigar smokers.
The effects of inhaling smoke from recreational drugs, such as marijuana and cocaine, are less studied than the effects of tobacco smoke. Metaplastic histologic and molecular changes similar to premalignant alterations have been described in the bronchial epithelium in habitual smokers of marijuana or cocaine.
A clear association has not been fully established, however, between such inhalant drug use and lung cancer. A case-control study showed that there is an 8% increased risk for lung cancer for each joint-year of marijuana smoking after adjusting for tobacco cigarette smoking.
Similarly, there is a 7% increased risk for lung cancer for each pack-year of cigarette smoking after adjusting for marijuana smoking. The relationship between cocaine smoking and lung cancer is not well studied.
The term, never smokers, refers to persons who have smoked fewer than 100 cigarettes in their lifetime, including lifetime nonsmokers. Most studies that track the trend of lung cancer rates often include both smokers and never smokers, and few studies independently study the trends over time for never smokers because of the limited longitudinal collection and the limited reliability of smoking information in population-based registries. From what is available, however, the overall global statistics estimate that 15% of lung cancers in men and up to 53% in women are not attributable to smoking, with never smokers accounting for 25% of all lung cancer cases worldwide.
The age-adjusted rate for lung cancer in never smokers (ages 40–79 years) ranged from 11.2 to 13.7 per 100,000 person-years for men and from 15.2 to 20.8 per 100,000 person-years for women. The rates are 12 to 30 times higher in current smokers of the same age group.
The incidence of lung cancer in never smokers seems to have a geographic variation. For example, a series following 12,000 patients with lung cancer in California found a dramatic increase in bronchoalveolar carcinoma in never smokers from 19% during 1995 to 1999 to 26% during 1999 to 2003.
The percentage of other types of lung cancer in never smokers also increased from 8.6% to 9.4%. Another study in the United States found a small but statistically significant increase in the mortality rate in women with non–smoking-associated lung cancers from 12.3% in the years 1959 to 1972 to 14.7% in the years 1982 to 2000.
A European case-control study, however, comparing data from 1950 and 1990, showed no significant change in the percentage of never smokers in male lung cancer patients and a decrease in the percentage of never smokers among female lung cancer patients.
Two major epidemiologic trends seem to be emerging in lung cancer in never smokers: (1) women are more frequently affected than men and (2) it is more prevalent in certain parts of the world, such as Asia.
Although all histologic types of lung cancer are associated with cigarette smoking, in smokers the association is stronger for SCLC and for squamous cell carcinoma. In contrast, adenocarcinoma of the lung is more common in never smokers (62% vs 18%, based on 5144 cases
Although there has been no predominant causal factor that can fully explain lung cancer in never smokers, the risk factors considered important for never smokers include secondhand smoke; radon exposure; environmental exposures, such as indoor air pollution, asbestos, and arsenic; history of lung disease; and genetic factors.
A population-based case-control study in Canada found that occupational exposures, history of lung disease, and family history of early-onset cancer were important risk factors for lung cancer among never smokers.
In this study, potential environmental sources of increased risk included exposure to solvents, paints, or thinners; welding equipment; and smoke, soot, or exhaust. This finding is particularly important because there are few data on occupational exposures and lung cancer among never smokers. Other studies have also shown an association between lung cancer in never smokers and a family history of lung cancer, a finding that suggests a role for genetic factors.
Specific genetic factors in these studies have not been identified. Some studies, however, suggest the role of the epidermal growth factor receptor gene (EGFR) pathway, the human repair gene (hMSH2), and various cytochrome P450 and glutathione-S-transferase enzymes.
No unique susceptibility gene has been identified that distinguishes lung cancers in never smokers from smokers. Recent data have shown, however, an increased frequency of EGFR mutations in lung adenocarcinomas of never smokers, especially in Asian cohorts (Fig. 13).
Despite this potential delayed diagnosis and later presentation of lung cancer in never smokers, the survival rate for never smokers is better than for smokers, independent of stage of disease, treatment received, and presence of comorbidities.
A multivariate analyses of lung adenocarcioma found that the never smoking status was an independent predictor of improved survival (23% 5-year survival rate for never smokers and 16% for current smokers).
Such findings have suggested that the cancer in never smokers may display a distinct biologic and natural history. There are also epidemiologic, clinicopathologic, and molecular differences between lung cancers in never smokers and smokers, differences that have led some investigators to suggest that lung cancer in never smokers may be a different disease. Microarray gene-profiling studies have found that lung adenocarcinomas are heterogeneous, and the profiles of cancer in smokers and never smokers are different.
In 2010, the first genome-wide association study (GWAS) reported genetic variations in chromosome 13q31.3 that altered the expression of glypican 5 (GPC5), a heparin sulfate proteoglycan with many known functions involving cell growth and differentiation and tissue responses.
Another GWAS focusing on lung adenocarcinomas in female Han Chinese never smokers in Taiwan identified genetic variation in the CLPTM1L-TERT locus of chromosome 5p15.33 as associated with risk for lung cancer in this population.
This 5p15.33 chromosome contains two well-known genes, telomerase reverse transcriptase (TERT) and cleft lip and palate transmembrane 1-like (CLPTM1L), both of which have been implicated in carcinogenesis.
There is a genetic component to the pathogenesis of lung cancer, whether it relates to host susceptibility to lung cancer, with or without exposure to cigarette smoke to the development of certain types of lung cancer, or to an individual’s responsiveness to biologic therapies. A lung cancer risk prediction analysis developed by Spitz and colleagues
incorporated multiple variables, such as smoking history, exposure to environmental tobacco smoke, occupational exposures to dusts and to asbestos, and family history of cancer. They showed the influence of a family history of cancer on the risk for lung cancer in never smokers, former smokers, and current smokers (Table 1). Cassidy and colleagues
reviewed the molecular epidemiology of lung cancer, focusing on host susceptibility genetic markers to lung carcinogens. (See the article by Larsen and Minna elsewhere in this issue.) The susceptibility genetic factors include high-penetrance, low-frequency genes; low-penetrance, high-frequency genes; and acquired epigenetic polymorphisms. Takemiya and colleagues
showed the association of lung cancer with rare mendelian cancer syndromes, such as Bloom and Werner syndromes. Studies on familial aggregation have supported the hypothesis that there is a hereditary component to the risk for lung cancer. These familial association approaches have been used to discover high-penetrance, low-frequency genes. A meta-analysis involving 32 studies showed a 2-fold increased risk for lung cancer in persons with a family history of lung cancer with an increased risk also present in nonsmokers.
using family linkage approaches, reported the first association of familial lung cancer to the region on chromosome 6q23–25 (146cM–164cM). The addition of smoking history to the effect of this inheritance was associated with a 3-fold increase risk for lung cancer.
There have also been many studies on candidate susceptibility genes that are of low penetrance and high frequency. The approach has been to target genes known to be involved in the absorption, metabolism, and accumulation of tobacco or other carcinogens in lung tissue. For example, genetic polymorphisms encoding enzymes involved in the activation and conjugation of tobacco smoke compounds, such as PAHs, nitrosamines, and aromatic amines, have been widely studied. Metabolism of these compounds occurs through either phase I enzymes (oxidation, reduction, and hydrolysis) or phase II (conjugation) enzymes. Some of the frequently studied enzymes in this system include CYP1A1, the glutathione S-transferases (GST), microsomal epoxide hydrolase 1 (mEH/EPHX1), myeloperoxidase (MPO), and reduced form of nicotinamide adenine dinucleotide phosphate quinine oxidoreductase 1 (NQO1). Polymorphisms in CYP1A1 and their association with lung cancer risks have been conflicting. A meta-analysis involving 16 studies by Le Marchand and colleagues
showed no significant risk associated with the CYP1A1 Ile462Val allele; however, in pooled analysis, a significant 55% increased risk for squamous cell carcinoma in whites was observed, especially in women and nonsmokers. GST gene products help conjugate electrophilic compounds to the antioxidant glutathione. GSTM1 in its null form occurs in 50% of the population, and studies by Benhamou and colleagues
showed an 18% increase risk for lung cancer among persons who were GSTMI null, but this significant association was not present when the analysis was limited to larger studies only. Amos and colleagues
performed a GWAS scan of tagged single nucleotide polymorphisms in histologically confirmed NSCLC in an effort to identify common low-penetrance alleles that influence lung cancer risk. They identified a susceptibility locus for lung cancer at chromosome 15q25.1, a region that contains the nicotinic acetylcholine receptor genes.
Results from the many candidate gene polymorphism studies focusing on a single polymorphism in one gene have been mixed. This has led to studies to look at gene-gene interactions, which require even a larger study population. For example, Zhou and colleagues
studied the interaction between variants in genes coding for NAT2 (which activates arylamine cigarette smoke metabolites and deactivates aromatic amines) and mEH (which activates PAHs and deactivates various epoxides). They found significant interactions between NAT2 variants associated with certain acetylation pheynotype and mEH variants associated with certain activity level with the risk of lung cancer. For example, a 2-fold increase risk for lung cancer was observed in 120 pack-year smokers who had the NAT2 slow-acetylation and mEH high-activity genotype. Alternatively, in nonsmokers, a 50% decrease risk for lung cancer was observed among persons with the combined NAT2 slow-acetylation and mEH high-activity genotype. Susceptibility to carcinogenic agents may also be affected by individual differences in mutagen sensitivity. Spitz and colleagues
reviewed the phenotypic studies of DNA repair capacity and lung cancer risks.
Polymorphisms in genes involved in DNA repair enzymes active in base excision repair (XRCC1 and OGG1), nucleotide excision repair (ERCC1, XPD, and XPA), and double-strand break repair (XRCC3), and different mismatch repair pathways have also been studied as they relate to lung cancer risks. Chronic inflammation in response to repetitive tobacco exposure has been theorized as involved in lung tumorigenesis. Genes encoding for the interleukins (IL-1, IL-6, and IL-8). The cyclooxygenase enzymes (eg, COX-2) involved in inflammation, or the metalloproteases (MMP-1, MMP-2, MMP-3, and MMP-12) involved in repair during inflammation have been associated with lung cancer risk. Several cell cycle–related genes have been implicated in lung cancer susceptibility, including the tumor suppressor genes p53 and p73, mouse double minute 2 (MDM2), and the apoptosis genes encoding FAS and FASL.
noted that the combined risk for lung cancer was greater in individuals with mutagen sensitivity who smoked than in persons with either smoking or mutagen sensitivity characteristics alone. DNA adducts can be measured as biomarkers to represent the degree of carcinogenesis. Several of the lung cancer susceptibility genes (discussed previously) have been associated with increased levels of DNA adducts. Acquired or epigenetic changes to DNA chromosome can also lead to increased lung cancer susceptibility. These events include changes, such as DNA methylation, histone deacetylation, and phosphorylation, all of which can affect gene expression. Despite many genetic association studies, the specific genes responsible for the enhanced risk for lung cancer remain poorly understood. Work is under way to pool findings to achieve greater study sample sizes in collaborative efforts, such as the Genetic Susceptibility to Environmental Carcinogens and the International Lung Cancer Consortium.
Lung cancer susceptibility is determined at least in part by host genetic factors. Persons with genetic susceptibility might therefore be at higher risk if they smoke tobacco. As technology advances, it may be possible to target subgroups identified as genetically high risk for lung cancer for specific interventions, including intensive efforts at smoking cessation, screening, and prevention programs.
Lung cancer surpassed breast cancer as the leading cause of cancer deaths in women in the late 1980s, and now almost twice as many women die of lung cancer than breast cancer.
Since 1950 there has been more than a 600% increase in the lung cancer mortality rate in women. In the United States, the cigarette smoking rate for women increased during the period from 1930 to 1960, and this increase was followed two decades later by an increase in lung cancer in women starting in 1960.
Cigarette smoking peaked during World War II among men born in the 1920s. The smoking rate in women peaked approximately a decade later among those who were born in the 1930s. Lung cancer deaths are expected to keep falling in both genders because older men and women and their younger counterparts smoke less. Smoking prevalence is higher among men (23.1%) than women (18.3%); however, this difference is narrowing.
There has been a drop of 2.5% in lung cancer deaths among men and a 0.9% decline in lung cancer deaths in women. Even though the overall age-adjusted lung cancer incidence is still higher in men than women, this difference is decreasing due to a continued decrease in the male incidence of lung cancer. Cigarette smoking remains the most important factor for the development of lung cancer in women with some suggesting up to 80% of cases in women are related to smoking.
Alternatively, for never smokers (discussed previously), the age-adjusted incidence rate of lung cancer is higher for women than men based on the compilation of several prospective cohort studies (14.4–20.8 per 100,000 person-years for women compared with 4.8–13.7 per 100,000 person-years for men).
Whether women are more or less susceptible than men to the carcinogenic effects of cigarette smoke is controversial. The American Cancer Society Cancer Prevention Study II, which followed 1 to 2 million subjects between 1982 and 1988, reported an overall risk for lung cancer in women smokers of 11.94, compared with an overall risk of 22.36 in male smokers, after taking into account the intensity of smoking.
A study using the American Health Foundation data found that the odds ratio (OR) for the major lung cancer types has been consistently higher for women than for men at every level of exposure to cigarette smoke.
The dose-response ORs for lung cancer in women were 1.2-fold to 1.7-fold higher than in men. A Canadian case-control study of male–female differences in lung cancer covering the period 1981 to 1985 showed that with a history of 40 pack-years of cigarette smoking relative to lifelong nonsmoking, the OR for women developing lung cancer was 27.9 versus 9.6 in men.
In both these studies, the increase in lung cancer risk held for all major histologic types.
The observed gender differences in susceptibility may be related to gender-related differences in nicotine metabolism and in metabolic activation or detoxification of lung carcinogens. Such gender differences in clearance of plasma nicotine by cytochrome P450 enzymes have been reported. For example, several reports have commented on gender differences in lung cancer observed at the molecular level. Ryberg and colleagues
noted that women with lung cancer have higher levels of DNA adducts than men. Such patients might be anticipated more susceptible to carcinogens, which might explain why women seem to develop lung cancer with lower-intensity cigarette exposure. Furthermore, hormonal factors may also play a role in susceptibility. A case-control study showed that estrogen replacement therapy was significantly associated with an increased risk for adenocarcinoma (OR 1.7), whereas the combination of cigarette smoking and estrogen replacement increased that risk substantially (OR 32.4).
Conversely, early menopause (age 40 years or younger) was associated with a decreased risk for adenocarcinoma (OR 0.3). More recent large randomized studies suggest that the use of hormonal therapies, such as estrogen and progestin, is associated with an increased risk for lung cancer in women.
The observed risk was proportional to the duration of hormone exposure, with approximately 50% increased risk for those who used hormone replacement therapy for 10 years or longer. Two studies as part of the Women’s Health Initiative found a statistically nonsignificant trend toward increased incidence of NSCLC and an increased number of deaths from lung cancer in women taking hormone therapy compared with those taking placebo.
A second issue is whether cigarette smoking may be associated with a higher risk for nonmalignant lung disease in women than in men. Neither of two large population studies, the British Doctors Study in the United Kingdom
suggest that cigarette smoking may be more harmful to the pulmonary function in women than in men. In this study, changes in forced expiratory volume in the first second of expiration (FEV1) and maximal midexpiratory flow rate increased with increasing pack-years more rapidly in women smokers than in their male counterparts. These changes were independent of age, height, and weight. Beck and colleagues
in a study of 4690 white subjects found that for a given level of smoking, women had more changes in FEV1 and maximal expiratory flow at 25% and 50% of vital capacity at a younger age (15–24 years) than men (40–45 years). Because smokers with spirometric evidence of airway obstruction are at higher risk for lung cancer, the suggestion that women have increased susceptibility to smoking-induced airway disease may be important in the consideration of their risk for lung cancer.
noted that a greater percentage of cancers in nonsmokers occurred in women than men. The number of women in that study was relatively small, however, and few women had at that time smoked for the duration of decades. Since then, it has become clear that women never smokers are more likely than male never smokers to develop lung cancer. In a case-control study by Zang and Wynder
of 1889 lung cancer subjects and 2070 control subjects, the proportion of never smoking lung cancer patients was more than twice as high for women than for men. The reasons for this finding are not clear, but speculation has been raised regarding the potential of women having greater susceptibility to nontobacco environmental carcinogens or increased exposure to ETS or the existence of gender-linked differences in the metabolism of nontobacco environmental carcinogens.
Race and Ethnicity
Race is a complex variable that often has a strong socioeconomic association. Racial differences in disease states can shed light, however, on the specific issues of a particular subpopulation. Menck
showed that the incidence of lung cancer is substantially higher among blacks and Native Hawaiians and other Polynesians and lower among Japanese Americans and Hispanics than among whites in the United States. These differences initially have been attributed to the variations in cigarette smoking pattern among the different ethnic and racial groups. Recent smoking data show that among the different groups, Asians (9.9%) had the lowest smoking prevalence in the United States, whereas American Indians and Alaska Natives (32.4%) had significantly higher prevalence than the other groups.
Smoking prevalence among whites (22%) and blacks (21.3%) were significantly higher than among Hispanics (15.8%). The Department of Health and Human Services reported, however, that the age-adjusted prevalence of cigarette smoking was similar among blacks and whites (30.1% and 27.3%, respectively). In addition, only 8% of black smokers smoked at least 25 cigarettes per day compared with 28% of white smokers. Native Hawaiians also had higher rates of lung cancer than whites and Asians despite having similar smoking habits. Haiman and colleagues
reported in their Multiethnic Cohort Study that among participants who smoked no more than 30 cigarettes per day, black Americans and Native Hawaiians had significantly greater risk for lung cancer than did whites. The relative risk for lung cancer among subjects smoking less than 20 cigarettes per day were 0.21 to 0.39 for Japanese Americans and Latinos, and 0.45 to 0.57 for whites as compared with black Americans. The differences in lung cancer risks were not significant, however, among all racial groups who exceeded 30 cigarettes per day of smoking. Recent SEER report based on data from 2004 to 2008 showed that black men, but not black women, in the United States had a higher age-adjusted incidence of lung cancer than their white counterparts at all age groups (Fig. 14).
Smokers with a history of early-onset lung cancer in a first-degree relative have a higher risk for lung cancer with increasing age than smokers without such a family history. Coté and colleagues
showed in a case-control study that first-degree relatives of black persons with early-onset lung cancer have a greater risk for lung cancer than their white counterparts (25.1% vs 17.1%, respectively). These cumulative differences in risk for lung cancer among blacks and whites are further amplified by increasing cigarette smoking exposure. The explanation for these observed racial or ethnic variations in risk for lung cancer is not known. Black Americans also have higher mortality rates from lung cancer than white Americans.
This difference in mortality rates has been attributed not only to the higher incidence rates but also to the poorer survival of black patients with lung cancer than white patients. For example, from 1995 to 2000, the 5-year survival rate was 14.3% lower in black Americans compared with white Americans. The reasons for these racial differences are not known. Brooks and colleagues
hypothesized a potential role for greater use of menthol cigarettes among black Americans than among white Americans (69% vs 22%) or the deeper inhalation of menthol cigarettes compared with nonmenthol cigarettes. No evidence, however, supports this hypothesis.
The average age of most populations in developed nations is increasing, and cancer is a disease of the elderly. Although smoking prevalence is lowest among persons aged 65 years and older (9.3%) compared with persons aged 18 to 24 years (21.4%), 25 to 44 years (23.7%) and 45 to 64 years (22.6%),
(see Fig. 14), more than 65% of patients with lung cancer are older than 65. Specifically, 31.1% of patients with lung cancer are between 65 and 74 years, 29% between 75 and 84 years, and 8.3% are 85 years old and older.
The mean age at the time of diagnosis is over 70. This difference between lower current smoking prevalence and the higher cancer rate in the elderly population likely reflects heavy smoking history in current elderly population. In the past decade, the incidence and mortality from lung cancer have decreased among persons aged 50 years and younger but have increased among persons aged 70 years and older.
The 5-year survival rate for lung cancer decreases incrementally with age for both genders (Fig. 15). “Older patients” are usually considered those older than 70 years with the “very elderly” those 80 years or older. Patients older than 80 years constitute 14% of all patients with lung cancer in the United States but account for almost a quarter of all lung cancer deaths. It has been estimated that the number of lung cancer patients aged 85 years and older will quadruple by 2050. Few studies have examined management of the elderly population with lung cancer. Recent reviews concluded that elderly patients, specially the functionally fit elderly, with lung cancer can benefit from many of the treatments used for younger patients, including surgery for early-stage disease and single-agent chemotherapy for advanced disease.
Vitamin A has both an animal (retinol) and a vegetable (carotenoid) source; the vegetable component only has been shown to have protective effects against lung cancer. In particular, β-carotene, a prominent carotenoid, has been shown to have the greatest protective effect against lung cancer.
One of the most widely cited reports of the effect of diet on the development of cancer was a prospective survey of approximately 2000 men aged 40 to 55 years employed by the Western Electric Company where detailed dietary histories were recorded in 1957 and followed for more than 19 years.
evaluated 27 such studies published before 1994 and concluded that persons in the lowest quartile of carotene intake had an approximately 50% to 100% increase in lung cancer risk compared with persons in the highest quartile of carotene intake. In response to these positive observations, three large-scale intervention trials have been conducted to try to determine the relationship between vitamin supplementations and lung cancer. Unfortunately, these studies showed that vitamin supplementation did not reduce lung cancer risk and in some circumstances increased the incidence of lung cancer. The Alpha-Tocopherol, Beta Carotene Cancer Prevention (ATBC) Study was a randomized, double-blind, placebo-controlled trial designed to determine whether daily supplementation of α-tocopherol, β-carotene, or both could reduce the incidence of cancers, including lung cancer.
The study enrolled 29,133 male smokers aged 50 to 60 years in Finland. Unexpectedly, a higher than expected mortality, primarily due to lung cancer and heart disease, was observed in the group receiving β-carotene. Omenn and colleagues
then reported results of the Beta-Carotene and Retinol Efficacy Trial (CARET), also a randomized, double-blind, placebo-controlled study. The study was intended to determine whether dietary supplementation with β-carotene, vitamin A, or both would decrease the incidence of lung cancer. It enrolled 18,314 men and women considered at increased risk for lung cancer. The CARET study was stopped 21 months early because of “clear evidence of no benefit and substantial evidence of harm” in the group that received β-carotene and retinol palmitate, especially women.
The group that received both vitamin A and β-carotene had a 17% increase in mortality and a 28% increase in the number of lung cancers compared with placebo. A third randomized, double-blind, placebo-controlled trial, the Physicians’ Health Study, evaluated the effect of β-carotene in 22,071 male physicians
; 11% of the participants were current smokers and 39% former smokers at the onset of the trial. Over 12 years of follow-up, neither benefit nor harm in terms of malignancy or cardiovascular disease was demonstrated. The dose of β-carotene in this trial was lower than in both the ATBC trial and the CARET study.
Because of the findings of the ATBC and CARET trials, the use of supplemental β-carotene and vitamin A is discouraged. There have also been suggestions that low dietary intake of certain minerals, including magnesium, zinc, copper, and iron, is associated with increased lung cancer risk; however, later prospective cohort studies observed no significant associations between total mineral intake and lung cancer risk.
The role of dietary supplementation in cancer chemoprevention is currently unsettled. These studies should serve as a reminder, however, that indiscreet and excessive intake of vitamins or other chemicals can be potentially harmful.
A diet rich in fruits and vegetables has been linked to decreased cancer incidence as suggested by a large cohort study in the Netherlands, with the protective effects stronger in current than in former smokers.
In this study, no specific type of vegetable or fruit was identified as particularly responsible for the effect. Consumption of vegetables described as cruciferous, such as broccoli and cabbage, which are rich in isothiocyanates, has some protective effect against lung cancer.
When study participants were stratified according to their GSTM1 and GSTT1 gene status, which are genes important at eliminating isothiocanates, the protective effect of the cruciferous vegetable consumption was best seen in subjects with the null gene.
It has been also further suggested that consuming fruits or vegetables raw rather than cooked is associated with a further reduction in risk for lung cancer because important carotenoids can be destroyed with cooking.
The study did show, however, that higher consumption of several botanic groups, such as rosaceae (apples, peaches, and strawberries), convolvulaceas (sweet potatoes and yams), and umbelliferae (carrots), was significantly inversely associated with lung cancer risk in men and in former smokers.
Flavonoid plant metabolites have properties described as antioxidant and antiproliferative. Flavonoids can be found in foods, such as berries, citrus fruits, tea, dark chocolate, and red wine. A prospective study showed the risk for lung cancer was lower in men with the highest total flavonoid intake compared with those with the lowest intake.
Despite the negative large-scale chemoprevention studies of vitamin supplementation and because of the large body of epidemiologic literature pointing to the benefits of fruits and vegetables, health authorities continue to recommend a balanced dietary intake of fruits and vegetables, including those containing β-carotene.
Because of the current obesity epidemic, discussion of dietary factors cannot be complete without mention of the role of excessive weight in lung cancer. In 2005, 23.25% of the world’s adult population (937 million people) was overweight and 9.8% (396 million) was obese with a body mass index (BMI) of greater than 30 kg/m2.
reported that there was an inverse association between BMI and lung cancer risk and obesity may even have a protective role. In the absence of cigarette smoking, however, the association between BMI and lung cancer was not significant. It has been proposed that the observed BMI and cancer association may be related to residual strong confounding effects of smoking itself.
Smokers have a lower BMI than nonsmokers, and they gain weight when they quit smoking. It has been suggested also that leanness was associated with increased lung cancer risk, but the studies were small and did not clearly exclude the confounding effects of smoking or pre-existing diseases.
after adjusting for pack-years of smoking and other relevant covariates in a female cohort, showed that there was evidence for inverse associations of BMI and lung cancer risk in current and former smokers; whereas in never smokers, BMI was positively associated with lung cancer. A different study showed that waist circumference was positively associated with lung cancer risk in the smokers.
Some nonmalignant diseases have been associated with an increased risk for lung cancer, the strongest association being with COPD. Tobacco smoking is the primary cause of both lung cancer and COPD. A study of women never smokers with lung cancer showed a statistically significant association between the presence of airflow obstruction and the development of lung cancer.
This conclusion is supported by the Lung Health Study in which 5887 male and female smokers with spirometric evidence of mild to moderate COPD were monitored over a 5-year period with or without smoking cessation counseling or bronchodilator therapy.
Lung cancer was the most common cause of death, accounting for 38% of all deaths and lung cancer deaths exceeded deaths from cardiovascular disease by nearly 50%. More recent studies in large cohorts have shown that COPD is significantly associated with an increased risk for lung cancer, especially in men.
Because COPD affects an estimated 40% to 70% of patients with lung cancer, a coexisting disease of lung cancer and COPD likely reflects a common smoking exposure. Potential confounders by age, gender, and smoking history or the effects of lung cancer on spirometry could have resulted in the overdiagnosis of COPD in patients with lung cancer. A recent study evaluated 602 patients with lung cancer and found that 50% of them had prebronchodilator pulmonary function test results consistent with a diagnosis of COPD with Global Initiative for Chronic Obstructive Lung Disease stage 2 and higher, independent of age, gender, and smoking history, with an OR of 11.6.
The prevalence of COPD in newly diagnosed lung cancer was 6-fold greater than matched smokers, suggesting that COPD itself is an important independent risk factor with potential relationship to the pathogenesis of lung cancer.
COPD is characterized by chronic inflammation that responds to corticosteroids, and chronic inflammation itself has been suggested as associated with lung cancer. A Dutch study found that the likelihood of developing lung cancer was increased if C-reactive protein, a measure of generalized inflammation, was greater than 3 mg/L compared with patients with lower levels (<1 mg/L).
A large retrospective study of patients with COPD patients found that the risk for lung cancer was lower among patients who took high-dose inhaled corticosteroids compared with patients taking lower doses or none at all.
tested whether α1-antitrypsin deficiency carriers have a higher risk for lung cancer, after adjusting for the effects of tobacco smoke exposure and COPD. Using a multiple logistic regression analysis, they found a significantly increased lung cancer risk (approximately 2-fold increased risk) among α1-antitrypsin deficiency carriers from two parallel case-control cohorts.
Interstitial fibrosis has also been associated with an increase in lung cancer risk. Hubbard and colleagues
evaluated 890 patients with cryptogenic fibrosing alveolitis (idiopathic pulmonary fibrosis) and 5884 control subjects and found that the incidence of lung cancer in patients with fibrosis was markedly increased, even after adjustment for smoking. Patients with such fibrosis had an OR for lung cancer of 8.25 compared with control subjects. Other fibrosing diseases, including asbestosis and scleroderma-related lung disease, also seem to have an increased association with lung cancer (asbestos-related disease is discussed later). The association of scleroderma with lung cancer, however, is weaker. A British study followed patients with idiopathic pulmonary fibrosis and found the incidence of lung cancer markedly increased compared with the general population.
Although the mechanisms by which pulmonary interstitial disease may predispose to malignancy are not clear, various hypotheses have been raised, including malignant transformation related to chronic inflammation, epithelial hyperplasia, impaired clearance of carcinogens, and infections.
Infection as a causative factor in lung cancer has been evoked but remains debatable. For example, oncogenic viruses have been proposed as a cause of lung cancer. Early studies on sheep pulmonary adenomatosis caused by the Jaagsiekte sheep retrovirus show pathologic similarities to human bronchioloalveolar carcinoma; however, there is not enough evidence to link these two diseases and prove the involvement of viruses in the development of human bronchioloalveolar carcinoma.
More recent findings have suggested a potential role for human papillomavirus (HPV), known to cause carcinoma in other tissues. The possible involvement of HPV in bronchial squamous cell lesions was first suggested by Syrjänen,
HPV DNA within squamous cell carcinoma lung cancer tissues has been detected. There is inconsistency, however, in the reported prevalence of infection by HPV in patients with lung cancer in different countries with racial and geographic variations. High incidence of HPV DNA in lung cancer has been reported in Asian cohorts, especially in nonsmokers; alternatively, studies in Western Europe failed to show an etiologic role of HPV in lung cancer.
HPV serotypes 16 and 18 are associated with lung cancer more than any other serotypes. E6 and E7 oncogenes from these HPV serotypes have been shown to immortalize human tracheal epithelial cells, which themselves are highly prone to genetic damage.
Currently, studies testing lung cancer specimens for HPV have yielded mixed results, and such variability of the frequency of HPV-positive lung cancer may be due to genetic susceptibility; methodologic approaches to detect HPV, such as those that involve the use of polymerase chain reaction (PCR); in situ hybridization and immunohistochemistry; and environmental and high-risk behavior variables. It would be interesting to see if HPV-directed vaccine for cervical cancer has any impact on the incidence of lung cancer.
Epstein-Barr virus, associated with Burkitt lymphoma and nasopharygeal carcinoma, has been strongly associated with lymphoepithelioma-like carcinoma, a rare form of lung cancer, in Asian patients, but this association has not been observed in the Western population.
More recently, DNA from Torque teno virus, a new virus, has been detected at high levels in idiopathic pulmonary fibrosis patients with lung cancer, and although suggestive that Torque teno virus infection might be associated with the development of lung cancer in idiopathic pulmonary fibrosis, more studies are needed to confirm these findings and determine their clinical significance.
Identification of C pneumoniae as etiologically related to lung cancer, whether independent of tobacco smoking or as a cofactor, could have profound implications, particularly in the area of lung cancer prevention. Using serology to define Chlamydia infection, multiple epidemiologic studies have reported higher lung cancer risk associated with positive serology compared with those without such evidence of infection.
Although there were concerns about measurement differences, the results were consistent and suggested a potentially novel association of this organism with lung cancer. Although Chlamydia is not a known oncogenic pathogen, some investigators have hypothesized that the inflammation resulting from the infection can lead to reactive oxygen species that can cause DNA damage, cell injury, and repair, increasing the risk of mutations, which can confer selective advantages that lead to cancer. Such infection can also act synergistically with cigarette smoking to increase the risk of lung cancer. Similar to the concerns related to the evidence for various viruses as causes of lung cancer, however, further investigations are needed to solidify the evidence for a causal role of Chlamydia in lung cancer.
Some studies have reported association of pulmonary tuberculosis with lung cancer.
A cohort study from Taiwan showed an increased risk for lung cancer in tuberculosis patients with hazard ratio of 3.3 after adjusting for confounding factors, such as COPD and smoking-related cancers other than lung cancer. The effect of tuberculosis was even greater when combined with COPD or with other smoking-related cancers.
Lung cancer has become a new challenge in HIV-infected individuals. AIDS-related mortality has dramatically fallen since the advent of highly active antiretroviral treatments; however, this has been accompanied by an increase in the proportion of deaths attributable to non–AIDS-defining tumors, especially lung cancer.
The increased risk of lung cancer relative to the general population of the same age seems due in part to the higher prevalence of smoking among HIV-infected patients. In a study of 2840 HIV-infected patients, HIV was associated with a hazard ratio of 3.6 for lung cancer after controlling for smoking status.
Although smoking is a key risk factor for lung cancer in HIV-infected patients, several other factors may contribute to the higher incidence of lung cancer. These include greater prevalence of co-infection with oncogenic viruses, such as human herpesvirus 8, HPV, and Epstein-Barr virus, and the potential direct effects of the HIV virus and the consequences of long-term immunosuppression.
Taken together, evidence suggests that infection may play a role in lung cancer; however, definite proof of a causal relationship is currently lacking.
Environmental Tobacco Smoke
Secondhand smoke, also referred to as ETS, can contribute to an increased risk for lung cancer with a dose-dependent relationship between the degree of exposure and the relative risk. One study showed that household exposure of 25 or more smoker-years before adulthood doubled the risk for lung cancer; exposure of less than 25 smoker-years did not increase risk. The investigators estimated that at least 17% of lung cancers in nonsmokers are attributable to exposure to high levels of ETS during childhood and adolescence.
Because nonsmokers exposed to ETS have an increased rate of smoke-related problems, including upper respiratory symptoms and eye irritation, and because there is an increased frequency of respiratory illnesses in children, it was suggested that the acknowledged carcinogenic effect of active tobacco smoking might also be present in those involuntarily exposed. Other reports showed an increased risk for lung cancer in nonsmoking women married to men who smoke.
This should be interpreted from the perspective that the background risk for lung cancer in a nonsmoker is low and contrasted with the 1000-fold increase of lung cancer risk in lifelong active smokers. Another study in nonsmoking women found that tobacco use by the spouse was associated with a 30% excess risk for all types of lung cancer.
Review of all the available evidence yielded an overall OR of 1.34 in lung cancer risk associated with ETS. In nonsmokers this translates into an approximately 30% increase of risk for lung cancer. At the same time, the US Department of Health and Human Services in a report on the health consequences of involuntary tobacco smoke exposure concluded that involuntary smoking is a cause of disease, including lung cancer, in healthy nonsmokers.
US Environmental Protection Agency, Office of Air and Radiation and Office of Research and Development. Respiratory Health Effects of Passive Smoking: Lung Cancer and Other Disorders. EPA 600-6-90-006F; 1992.
examined lung cancer mortality and ETS within the context of the American Cancer Society Cancer Prevention Study. These investigators performed a prospective comparative evaluation of 133,835 never smokers with smoking spouses versus 154,000 never smokers with nonsmoking spouses. They concluded that the relative risk for lung cancer in women with smoking husbands was 1.2, which represented an increase in lung cancer incidence of 20%. The relative risk in nonsmoking men with smoking wives was somewhat less but still elevated at 1.1. These figures are consistent with data from prior studies evaluating lung cancer risk from ETS. Pooled data from 8 such studies in the United States from 1981 to 1991 found the relative risk for lung cancer in nonsmokers living with smokers to be 1.23.
reported that male nonsmokers exposed to sidestream smoke generated by machine smoking of cigarettes had measurable carcinogenic metabolites in their urine. In the third National Health and Nutrition Examination Survey conducted between 1988 and 1991, Pirkle and colleagues
reported that a surprising 88% of nontobacco users had detectable levels of serum cotinine, a metabolite of nicotine, presumably from exposure to ETS. The presence of ETS is pervasive and harmful. Therefore, efforts on public smoking limitations will be of great benefit in this regard. With 19.8% of the American adult population still smoking, however, ETS will continue to be a major public health issue until cigarette smoking altogether is eliminated.
The exact number of cases of lung cancer due to involuntary smoking is difficult to calculate. Beckett, however, estimates that the number of lung cancer deaths in the United States attributable to ETS is comparable to the annual number caused by asbestos or radon.
In many parts of the world, wood is burned for cooking and heating purposes. Approximately 3 billion people worldwide rely on solid fuels as their primary source of domestic energy for cooking and heating. In China, for example, incomplete combustion of coal in homes has been linked with lung cancer.
A case-control study followed a group of residents living in underground dwellings who burn coal and unprocessed biomass, such as crop residues, wood, sticks, and twigs, for heating and cooking. They found that the OR for lung cancer associated with such coal use compared with that for biomass in the house was 1.29, after adjusting for smoking.
The IARC has recently classified indoor emissions from household coal combustion as a human carcinogen and emissions from biomass fuel primarily from wood as probable human carcinogen. A study using data from this consortium found that compared with nonsolid fuel users, predominant coal users (OR 1.64; in particular, coal users in Asia with OR 4.93), and predominant wood users in North American and European countries (OR of 1.21) exhibited higher risk for lung cancer.
A European cohort showed similar association of solid fuel use for heating and cooking with lung cancer risk; OR of lung cancer in lifetime users of solid fuel was 1.80; switching to nonsolid fuels resulted in lowered risk.
It has been suggested that the lung cancer that arise from wood smoke may behave differently from lung cancer due to tobacco smoke. Wood smoke exposure was found an important factor in predicting favorable response of NSCLC to tyrosine kinase inhibitor therapy.
Environmental Air Pollution
Air pollution has become a worldwide problem given the current staggering rate of globalization and industrialization. Wilkins
chronicled the most impressive example of the severe adverse effect of air pollution: the 1952 “great smog” of London, during which thousands of persons died in a week from heavy pollution. This led to the implementation of the Clean Air Act 4 years later. The effects of low levels of air pollution exposure over a longer period of time are harder to measure, especially the long-term and accumulative effects on lung cancer risks. Air pollution is worsening in developing countries; the highest concentrations of suspected particulates, sulfur dioxide, and smoke have been recorded in large cities of these countries. Outdoor air pollution has long been thought to increase the risk for lung cancers. Advances in analytic methods used to detect specific pollutants have helped investigators study the effects of such airborne particulates. Early studies by Pershagen
showed a relative risk for lung cancer of 1.44 for persons exposed to more than 29.3 μg/m3 of nitric oxide (as a measure of traffic air pollutant) over 21 to 30 years compared with exposures to lower than 12.8 μg/m3 of nitric oxide. Two large United States cohort studies by Dockery
suggest that there is an excess risk for lung cancer of approximately 19% per 10 μg/m3 increment in the long-term average exposure to fine particulates after adjustments for multiple confounding factors. Pope and coworkers
found as part of the Cancer Prevention Study II that fine particulate and sulfur oxide-related pollution were associated with 8% increased risk for lung cancer mortality for each 10 μg/m3 elevation in long-term average ambient concentration of fine particles less than 2.5 μm in diameter. Despite these studies, it is still difficult to pinpoint the carcinogenic role played by single constituents of air pollution.
Various potential carcinogenic components are thought to be emitted from different sources of fossil fuel combustion products. Cohen
suggested that there is a range gradient of relative risk for lung cancer associated with exposure to combustion products, from 7.0 to 22.0 in cigarette smokers, to 2.5 to 10.0 in coke oven workers, to 1.0 to 1.6 in residents of areas with high levels of air pollution, to 1.0 to 1.5 in nonsmokers exposed to environmental tobacco smoke. Diesel exhaust composed of a complex mixture of gases and fine particles represents an important component of air pollution. Some of these gaseous components, such as benzene, formaldehyde, and 1,3-butadiene, are suspected of causing or known to cause cancer in humans. Studies in the late 1980s concluded that there was a weak association between diesel engine exhaust exposure and cancer. Later work, however, that included two large independent meta-analyses by Lipsett and Campleman
provided strong support that occupational exposures to diesel exhaust, especially in persons in the trucking industry, is associated with an approximately 30% to 50% increase in the relative risk for lung cancer. Data linking gasoline engine exhaust and lung cancer are less compelling.
Several workplace substances have been suggested to be or have been proved carcinogens in the lung. The IARC has identified arsenic, asbestos, beryllium, cadmium, chloromethyl ethers, chromium, nickel, radon, silica, and vinyl chloride as carcinogens. The occupations associated with exposure to these agents are shown in Tables 3 and 4. In 2000, it was estimated that 10% of lung cancer deaths among men (88,000 deaths) and 5% among women (14,300 deaths) worldwide could be attributable to exposure to 8 occupational lung carcinogens, namely asbestos, arsenic, beryllium, cadmium, chromium, nickel, silica, and diesel fumes.
Asbestos is the most widely known and most common occupational cause of lung cancer. Asbestos is a class of naturally occurring fibrous minerals consisting primarily of 2 types: (1) serpentine (chrysotile) and (2) amphibole (amosite, crocidolite, and tremolites). Asbestos has been used commercially since the late 1800s, and its fire-retardant qualities and strength have made it useful in construction and insulating materials. As early as the 1940s in Germany, asbestos was noted as a lung carcinogen.
Asbestos exposure can also result in pleural and pulmonary manifestations. Asbestos-related pleural disease can present as effusion, pleurisy, or both. Chronic pleural involvement is seen as areas of pleural thickening (pleural plaques) that usually involve the parietal pleura and that are often calcified. The presence of pleural plaques does not herald the development of mesothelioma and has not been proved a marker of increased risk for lung cancer. Inhalation of asbestos fibers can result in parenchymal lung disease, specifically interstitial lung disease, known as asbestosis. All the major types of asbestos can cause interstitial lung disease, although amphibole fibers may be more fibrogenic than chrysotile fibers. The presentation of asbestosis is essentially identical to that of nonspecific interstitial lung disease as well as idiopathic pulmonary fibrosis. Asbestosis develops above a threshold fiber dose of approximately 25 to 105 fibers per mL per year, where the threshold dose is usually reached only in workers, including asbestos insulators, miners, millers, and textile workers, who have heavy occupational exposure.
The development of interstitial fibrosis usually requires prolonged exposure over months to years. Such fibrotic disease can follow shorter, more intense exposure, as occurs in shipyard workers. The latency period from exposure to presentation of disease is inversely proportional to exposure level. In the United States, the national rate of lung cancer in the form of mesothelioma is 13.8 per million population per year, with higher rates, exceeding 20 per million per year, in Maine, New Jersey, Pennsylvania, Washington, Wyoming, and West Virginia (Fig. 16).
The distinction between asbestos exposure and asbestosis is important because of the controversy as to which represents the actual risk factor for lung cancer. Two reviews discussing the extensive available epidemiologic data illustrate this controversy. Jones and colleagues
in their extensive literature review highlight several important points. First, it is widely recognized that lung fibrosis of many causes, including idiopathic pulmonary fibrosis and interstitial disease associated with connective tissue disease, is associated with an increased risk for lung cancer. Second, in animal experiments asbestos-exposed animals that developed lung cancer only when they also developed pulmonary fibrosis. Third, pleural plaques, a marker for asbestos exposure, have not proved a reliable marker for increased risk for lung cancer. These investigators conclude that the issue of whether asbestosis is a necessary precursor to asbestos-attributable lung cancer cannot be definitively settled. Their assessment, however, was that the available data strongly support that hypothesis. In contrast, in an extensive assessment of the medical literature Egilman and Reinert conclude, “asbestos meets accepted criteria for causation of lung cancer in the absence of clinical or histologic parenchymal asbestosis.”
in 2005 concluded that because of the relative insensitivity of chest radiographs and the uncertain specificity of histologic findings or CT, it is unlikely that epidemiologic studies alone can determine whether asbestos-related lung cancer arises only in the presence of pulmonary fibrosis. Recent studies have found that asbestos exposure was associated with a relative risk for lung cancer of 3.5 after adjusting for age, smoking, and vitamin intake.
This risk for lung cancer associated with asbestos exposure is dose-dependent but varied with the type of asbestos fiber exposure. The risk for lung cancer seems higher for workers exposed to amphibole fibers than for those exposed to chrysotile fibers, after adjusting for similar exposure level. The presence of interstitial fibrosis, such as in the form of asbestosis in persons exposed to asbestos, is associated with increased likelihood for lung cancer than patients with asbestos exposure without the associated fibrosis.
The study concluded that asbestosis was a better predictor of excess lung cancer risk than measures of asbestos exposure. Another study found excess risk for lung cancer was restricted to asbestos workers with radiographic evidence of asbestosis even though exposures to asbestos were similar to workers without such evidence.
noted that all persons living in industrialized countries have accumulated asbestos fibers in their lungs; in adults, the number of fibers is estimated in the millions. Asbestosis, however, requires prolonged and intense exposure to asbestos and does not occur at the level of everyday asbestos exposure. The risk for lung cancer from nonoccupational asbestos exposure in the general environment is extremely low. Moreover, Hughes and Weill
point out that if, as postulated, asbestosis is a necessary prerequisite to the development of cancer, the extrapolation of risk for lung cancer related to occupational asbestos exposure to the risk from exposure to asbestos in the general environment would substantially overestimate that risk. Another controversy in the area of asbestos and lung cancer is whether all types of fibers are carcinogenic. Epidemiologic and experimental data suggest that amphibole fibers are more carcinogenic than chrysotile.
In the United States, chrysotile has been by far the most commonly used type of asbestos. Thus, although all fibers may be carcinogenic, public concern about low-level asbestos exposure and lung cancer should be appropriately tempered.
Tobacco smoking clearly potentiates the observed carcinogenic effect of asbestos; however, the magnitude of the combined effect is not clear. It is also unclear whether the interaction of these two agents results in an additive or synergistic increase in the risk for lung cancer. When considering the addition of cigarette smoke exposure to asbestos, the risk for lung cancer is further increased. One report found that the risk for death from lung cancer in asbestos workers increased by 16-fold if the asbestos workers smoked more than 1 pack per day and by 9-fold if they smoked less than 1 pack per day compared with asbestos workers without significant smoking history.
The relative risk for lung cancer with asbestos exposure alone is 6-fold, with cigarette smoking alone 11-fold, but with exposure to both asbestos and cigarette smoke, the increase may be as high as 59-fold. The nature of the interaction in terms of relative risk, however, is again not clear. What is clear is that most lung cancers occur in asbestos-exposed workers who smoke. Smoking cessation should, therefore, be the most important goal of cancer prevention programs in this population, with particular targeting of the subgroup of workers with asbestosis. It is unclear if asbestosis is a marker for heavier exposure to asbestos or if the inflammation and fibrotic changes in the pathogenesis of asbestosis itself is mediating the cancer process. With recognition of the many health risks related to asbestos, its use has precipitously declined in the United States since the 1970s (Fig. 17).
Mining is the oldest occupation associated with lung cancer. An illness described as a wasting pulmonary disease of miners and metal smelters has been associated with early mortality. The cause of this illness at the time, known as miners’ phthisis, was variably attributed to dust or metal exposure, tuberculosis, or even inbreeding among mining communities. Early autopsy study performed on miners exposed to ores in the Central European mines documented that the process was actually neoplastic. Frank
points out that these same mines produced the material from which Marie Curie later isolated radium. Although the etiologic factors causing the increased lung cancer risk were originally speculated as dust-related pneumoconioses, arsenic, or cobalt, the actual carcinogens have been identified as radioactive materials, primarily radon and its decay products.
Radon (radon 222) is a naturally occurring decay product of radium 226, itself a decay product of uranium 238. Uranium and radium are ubiquitous in soil and rock, although in highly variable concentration. At usual temperatures, radon is released as a radium decay product as an inert radioactive gas. Radon itself decays with a half-life of 3.82 days into a series of radioisotopes, known as radon decay products (or radon daughters), that have half-lives measured in seconds to minutes. These products include polonium 218 and polonium 214, which emit alpha particles. α-Radiation is highly damaging to tissues including the respiratory epithelium. Inhalation of these radon decay products and subsequent alpha particle emission in the lung may cause damage to cells and genetic material. Ultimately, radon decay produces lead 210, which has a half-life of 22 years. Radon is a well-established carcinogen with extensive data available both as an occupational hazards as well as exposures experienced by the general population. Evidence from epidemiologic studies of underground miners shows a linear relationship between radon exposure and lung cancer risk.
It has been found that uranium miners in Germany exposed to radon and the decay products have an increased risk for lung cancer, especially 15 to 24 years after exposure and in miners younger than 55 years.
Pooled original data from 11 cohort studies of radon-exposed underground miners showed that almost 40% of all lung cancer deaths may be due to radon progeny exposure, with 70% of lung cancer deaths in never-smokers and 39% in smokers. Moreover, this report concludes that 10% of all lung cancer deaths might be due to indoor radon, with 11% of lung cancer deaths in smokers and 30% of lung cancers in never smokers.
Smokers and nonsmoking residents of smoking households are at increased risk for lung cancer even when radon levels are low. The combination of exposure to the two carcinogens is worse than exposure to either alone. The numbers of lung cancer cases reported in nonsmoking miners is small because miners have a high prevalence of cigarette smoking. In a study of underground uranium miners from Colorado, however, nonsmoking miners had a higher relative risk for lung cancer compared with all miners.
Such work emphasizes the potential importance of radon as a carcinogen in the nonsmoking population at large. Uranium mining has now ceased in the United States. Radon exposure, however, continues to be an occupational concern in nonuranium mining and underground work as well as in uranium and nonuranium mines around the world. In the United States, occupational exposure to radon is legislatively controlled. Individual exposure records are mandated for all workers in areas where the concentration of radon exceeds 0.3 work level, with an annual cumulative exposure limit of 4 work-level month. The Biological Effects of Ionizing Radiation IV study estimated that a 40-year exposure at this level would increase a person’s lifetime risk for lung cancer 2-fold.
This is at best an approximate estimate, however. Continued longitudinal evaluation of occupationally exposed persons is needed to improve understanding of the carcinogenic effects of radon.
In recent years, the possible risk for lung cancer in the general population associated with radon exposure has been a concern. The National Council on Radiation Protection and Measurements has identified radon and its decay products as the largest component of environmental radiation to persons living in the United States. These findings in conjunction with extrapolation of data collected in groups with high occupational radon exposure have escalated concern about the risks of lung cancer related to domestic radon. Radon is a ubiquitous indoor air pollutant in homes, and it has been projected that radon is the second leading cause of lung cancer after smoking. The concentration of radon gas in an environment varies depending on two factors: the richness of the source of radium and the degree to which the air around that source is ventilated. Therefore, certain sites may be more likely to have a high radon concentration, with the prototypical situation being underground mines with poorly ventilated passageways. In a 1991 survey of homes in the United States, Samet and colleagues
reported a mean indoor radon level of approximately 1.25 pCi/L. In this survey, the range of indoor radon levels was broad. Most homes had levels only slightly higher than outdoor environmental levels, but a few had levels ranging in excess of 100 pCi/L. The primary factor determining radon gas concentration in homes is the concentration of radium in the soil and rock beneath those structures. Building materials, well water, and natural gas are less common sources, usually contributing only minimally to indoor radon concentrations. Indoor-to-outdoor air exchange may also affect radon concentration within the home.
Broad concern for the public health implications of domestic radon exposure has been heightened by the documented carcinogenic effect of radon in miners as described. The potential for mutagenic and carcinogenic effects of low-level α radiation, however, has been an area of controversy. Several studies examining lung cancer risks from domestic exposure have been performed. In a meta-analysis of 8 such studies that included 4263 patients with lung cancer and 6612 controls, Lubin and Boice
concluded that greater residential exposure levels were associated with an increased overall relative risk for lung cancer of 1.14. This conclusion is consistent with extrapolation of risk from studies performed in miners as well as with actual calculated risks in miners with low cumulative radon exposure. This meta-analysis did not demonstrate any greater increase in lung cancer risk than what would be extrapolated from radon exposure in miners. Using miner-based risk models, it is now estimated that domestic radon may account for 7000 to 36,000 lung cancer deaths in the United States per year. There are studies that dispute this projection, however, or demonstrate no increased risk even with high indoor domestic radon levels.
concluded that use of a theoretic linear no-threshold relationship to extrapolate known risks in miners with high radon exposure levels to risk in persons with residential radon exposure grossly overestimates lung cancer risk. Cohen pointed out that the effects of low-dose, low-rate radiation have never been adequately evaluated, and he contested the assumptions inherent in extrapolation of high radon exposure in miners to domestic situations. Hei and colleagues
shed some insight into the effects of a single alpha particle hit to a cell as this is most relevant to radon exposure in the general population where the probability of multiple hits on a single cell is low given the level of environmental radon. They found that a majority of cells transversed by a single alpha particle survive such radon exposure. Up to 10% of cells can survive even up to 8 alpha particles traversals. Moreover, in the cells that survive such alpha particle exposure, the frequency of gene mutation after a single traversal was enhanced 2-fold, more with additional traversals by alpha particles. Therefore, small numbers of bronchial epithelial cells can be at significant risk for radiation-induced mutation in the setting of environmental radon levels. Assuming that genetic mutation may be an early step in induction of cancer, these data suggest that environmental and indoor radon exposure does indeed constitute a significant public health problem in its potential contribution to the development of lung cancer.
Other occupational carcinogens
Other lung carcinogens have been identified, relating to a wide array of occupations (see Tables 3 and 4). Worldwide, there are estimated 152,000 deaths from lung cancer and approximately 1.6 million disability-adjusted life years from lung cancer due to exposure to occupational exposures to carcinogens.
from the National Institute for Occupational Safety and Health estimated that approximately 9000 to 10,000 men and 900 to 1900 women per year in the United States develop lung cancer from exposure to occupational carcinogens. Although more than half of these are related to asbestos, a substantial number is attributable to other exposures. Furthermore, because these figures apply only to known carcinogens, they likely underestimate the actual number of lung cancer cases related to occupational exposures and represent another area in which prevention may play an important role.
Prevention of lung cancer
Multiple genetic, cellular, and local tissue alterations are involved in a chronic process that leads to lung carcinogenesis. The transformation of normal cells to preneoplastic cells to actual malignant cells involves changes that include DNA damages, genetic and epigenetic changes and the progression to unyielded proliferation of cells and invasion outside the boundaries of local tissues that is characterized as metastases. Exposure to various carcinogens alters normal cells long before clinically detectable invasive malignant tumors occur. Overwhelmingly, the major risk factor for lung cancer is cigarette smoking with a relative risk of 20 to 25 and an attributable risk of 85% to 90%.
The remaining risk factors contributing to lung cancer include environmental tobacco smoke, occupational exposure to asbestos and radon progenies, and diet. The incidence of lung cancer and therefore its related mortality can be reduced by early detection, treatment of disease, chemoprevention, and smoking avoidance and cessation.
Of these, only smoking prevention and cessation programs aimed at reducing smoking rates have been shown to reduce lung cancer risk.
Prevention of smoking initiation prevents the sequence of events leading to cancer. Despite intensive antismoking campaigns and widespread public awareness of the risks associated with smoking, there seems to be a committed smoking cohort that includes a 19.8% of the population of the United States.
reported two large case-control studies from approximately 1950 and from 1990 in the United Kingdom. In 1990, cessation of smoking had nearly halved what would have been the anticipated number of lung cancer cases. Lung cancer risk also seemed related to age at smoking cessation. For men who had stopped smoking at ages 60, 50, 40, and 30 years, the cumulative risks of lung cancer by age 70 years were 10%, 6%, 3%, and 2%, respectively. Jemal and colleagues,